To explore the potential role of TRIM25 in CRC therapy, we initially evaluated the TRIM25 level in 26 primary tumor tissues from patients with stage III CRC that were treated with OXA-based chemotherapy. The gene discussed is TRIM25; the disease is neoplasm.